Ardea Biosciences, Inc. – Product Pipeline Review – 2012
Summary
Global Market Direct’s pharmaceuticals report, “Ardea Biosciences, Inc. - Product Pipeline Review - 2012” provides data on the Ardea Biosciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ardea Biosciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ardea Biosciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Current R&D Portfolio of Ardea Biosciences, Inc.; Ardea Biosciences, Inc. - Key Therapeutics; Ardea Biosciences, Inc. - Pipeline Overview and Promising Molecules; Ardea Biosciences, Inc. - News; Ardea Biosciences, Inc. - Latest Updates; Ardea Biosciences, Inc. - Pipeline; Ardea Biosciences, Inc. - Discontinued/Dormant Projects
Summary
Global Market Direct’s pharmaceuticals report, “Ardea Biosciences, Inc. - Product Pipeline Review - 2012” provides data on the Ardea Biosciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ardea Biosciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ardea Biosciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Ardea Biosciences, Inc. - Brief Ardea Biosciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Ardea Biosciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Ardea Biosciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Ardea Biosciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Ardea Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Ardea Biosciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Ardea Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Ardea Biosciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Ardea Biosciences, Inc. and identify potential opportunities in those areas.
Current R&D Portfolio of Ardea Biosciences, Inc.; Ardea Biosciences, Inc. - Key Therapeutics; Ardea Biosciences, Inc. - Pipeline Overview and Promising Molecules; Ardea Biosciences, Inc. - News; Ardea Biosciences, Inc. - Latest Updates; Ardea Biosciences, Inc. - Pipeline; Ardea Biosciences, Inc. - Discontinued/Dormant Projects
Ardea Biosciences, Inc. Snapshot
Ardea Biosciences, Inc. Overview
Key Information
Key Facts
Ardea Biosciences, Inc. – Research and Development Overview
Key Therapeutic Areas
Ardea Biosciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ardea Biosciences, Inc. – Pipeline Products Glance
Ardea Biosciences, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ardea Biosciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ardea Biosciences, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Ardea Biosciences, Inc. – Drug Profiles
900 SERIES
Product Description
Mechanism of Action
R&D Progress
RDEA3170
Product Description
Mechanism of Action
R&D Progress
RDEA594
Product Description
Mechanism of Action
R&D Progress
RDEA594 + Allopurinol
Product Description
Mechanism of Action
R&D Progress
RDEA594 + Febuxostat
Product Description
Mechanism of Action
R&D Progress
Ardea Biosciences, Inc. – Pipeline Analysis
Ardea Biosciences, Inc. – Pipeline Products by Therapeutic Class
Ardea Biosciences, Inc. – Pipeline Products By Target
Ardea Biosciences, Inc. – Pipeline Products by Route of Administration
Ardea Biosciences, Inc. – Pipeline Products By Mechanism of Action
Ardea Biosciences, Inc. – Recent Pipeline Updates
Ardea Biosciences, Inc. - Dormant Projects
Ardea Biosciences, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Iseganan
Ardea Biosciences, Inc. – Company Statement
Ardea Biosciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Ardea Biosciences, Inc., Recent Developments
Ardea Biosciences, Inc.- Press Release
Dec 01, 2009: Ardea Biosciences Reports Positive Results From Combination Of RDEA594 And Febuxostat
Jul 20, 2009: Ardea Biosciences Initiates Phase IIb Clinical Trial of RDEA594, Lead Product Candidate For The Treatment Of Gout
Apr 20, 2009: Ardea Biosciences Announces Positive Results From A Phase I Study Of Lead Hyperuricemia And Gout Candidate, RDEA594 And A Phase IIa Study of RDEA594's Prodrug, RDEA806
Financial Deals Landscape
Ardea Biosciences, Inc., Deals Summary
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Ardea Biosciences Acquires Intellectual Property And Other Assets From Valeant Pharma
Licensing Agreements
Ardea Biosciences Enters Into License Agreement With Bayer HealthCare
Equity Offering
Ardea Biosciences Completes Public Offering Of Common Stock For $166 Million
Ardea Biosciences Completes Exercise Of Underwriters’ Over-allotment Option For $82 Million
Ardea Biosciences Completes Public Offering Of $80.5 Million
Ardea Biosciences Completes Private Placement Of $31 Million
Ardea Biosciences Completes Private Placement $40 Million
Intrabiotics Pharma Completes Public Offering Of $44.85 Million
Acquisition
AstraZeneca To Acquire Ardea Biosciences, Gout Drug Maker, For $1.26 Billion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Ardea Biosciences, Inc., Key Information
Ardea Biosciences, Inc., Key Facts
Ardea Biosciences, Inc. – Pipeline by Indication, 2012
Ardea Biosciences, Inc. – Pipeline by Stage of Development, 2012
Ardea Biosciences, Inc. – Monotherapy Products in Pipeline, 2012
Ardea Biosciences, Inc. – Combination Treatment Modalities in Pipeline, 2012
Ardea Biosciences, Inc. – Phase III, 2012
Ardea Biosciences, Inc. – Phase II, 2012
Ardea Biosciences, Inc. – Phase I, 2012
Ardea Biosciences, Inc. – Pre-Clinical, 2012
Ardea Biosciences, Inc. – Pipeline By Therapeutic Class, 2012
Ardea Biosciences, Inc. - Pipeline By Target, 2012
Ardea Biosciences, Inc. – Pipeline By Route of Administration, 2012
Ardea Biosciences, Inc. – Pipeline Products By Mechanism of Action, 2012
Ardea Biosciences, Inc. – Recent Pipeline Updates, 2012
Ardea Biosciences, Inc. - Dormant Developmental Projects,2012
Ardea Biosciences, Inc. - Discontinued Pipeline Products, 2012
Ardea Biosciences, Inc., Subsidiaries
Ardea Biosciences, Inc., Deals Summary
Ardea Biosciences Acquires Intellectual Property And Other Assets From Valeant Pharma
Ardea Biosciences Enters Into License Agreement With Bayer HealthCare
Ardea Biosciences Completes Public Offering Of Common Stock For $166 Million
Ardea Biosciences Completes Exercise Of Underwriters’ Over-allotment Option For $82 Million
Ardea Biosciences Completes Public Offering Of $80.5 Million
Ardea Biosciences Completes Private Placement Of $31 Million
Ardea Biosciences Completes Private Placement $40 Million
Intrabiotics Pharma Completes Public Offering Of $44.85 Million
AstraZeneca To Acquire Ardea Biosciences, Gout Drug Maker, For $1.26 Billion
LIST OF FIGURES
Ardea Biosciences, Inc. – Pipeline by Indication, 2012
Ardea Biosciences, Inc. – Pipeline by Stage of Development, 2012
Ardea Biosciences, Inc. – Monotherapy Products in Pipeline, 2012
Ardea Biosciences, Inc. – Combination Treatment Modalities in Pipeline, 2012
Ardea Biosciences, Inc. – Pipeline By Therapeutic Class, 2012
Ardea Biosciences, Inc. - Pipeline By Target, 2012
Ardea Biosciences, Inc. - Pipeline Products By Mechanism of Action, 2012
Ardea Biosciences, Inc. Overview
Key Information
Key Facts
Ardea Biosciences, Inc. – Research and Development Overview
Key Therapeutic Areas
Ardea Biosciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Ardea Biosciences, Inc. – Pipeline Products Glance
Ardea Biosciences, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Ardea Biosciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Ardea Biosciences, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Ardea Biosciences, Inc. – Drug Profiles
900 SERIES
Product Description
Mechanism of Action
R&D Progress
RDEA3170
Product Description
Mechanism of Action
R&D Progress
RDEA594
Product Description
Mechanism of Action
R&D Progress
RDEA594 + Allopurinol
Product Description
Mechanism of Action
R&D Progress
RDEA594 + Febuxostat
Product Description
Mechanism of Action
R&D Progress
Ardea Biosciences, Inc. – Pipeline Analysis
Ardea Biosciences, Inc. – Pipeline Products by Therapeutic Class
Ardea Biosciences, Inc. – Pipeline Products By Target
Ardea Biosciences, Inc. – Pipeline Products by Route of Administration
Ardea Biosciences, Inc. – Pipeline Products By Mechanism of Action
Ardea Biosciences, Inc. – Recent Pipeline Updates
Ardea Biosciences, Inc. - Dormant Projects
Ardea Biosciences, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Iseganan
Ardea Biosciences, Inc. – Company Statement
Ardea Biosciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Ardea Biosciences, Inc., Recent Developments
Ardea Biosciences, Inc.- Press Release
Dec 01, 2009: Ardea Biosciences Reports Positive Results From Combination Of RDEA594 And Febuxostat
Jul 20, 2009: Ardea Biosciences Initiates Phase IIb Clinical Trial of RDEA594, Lead Product Candidate For The Treatment Of Gout
Apr 20, 2009: Ardea Biosciences Announces Positive Results From A Phase I Study Of Lead Hyperuricemia And Gout Candidate, RDEA594 And A Phase IIa Study of RDEA594's Prodrug, RDEA806
Financial Deals Landscape
Ardea Biosciences, Inc., Deals Summary
Ardea Biosciences, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Ardea Biosciences Acquires Intellectual Property And Other Assets From Valeant Pharma
Licensing Agreements
Ardea Biosciences Enters Into License Agreement With Bayer HealthCare
Equity Offering
Ardea Biosciences Completes Public Offering Of Common Stock For $166 Million
Ardea Biosciences Completes Exercise Of Underwriters’ Over-allotment Option For $82 Million
Ardea Biosciences Completes Public Offering Of $80.5 Million
Ardea Biosciences Completes Private Placement Of $31 Million
Ardea Biosciences Completes Private Placement $40 Million
Intrabiotics Pharma Completes Public Offering Of $44.85 Million
Acquisition
AstraZeneca To Acquire Ardea Biosciences, Gout Drug Maker, For $1.26 Billion
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Ardea Biosciences, Inc., Key Information
Ardea Biosciences, Inc., Key Facts
Ardea Biosciences, Inc. – Pipeline by Indication, 2012
Ardea Biosciences, Inc. – Pipeline by Stage of Development, 2012
Ardea Biosciences, Inc. – Monotherapy Products in Pipeline, 2012
Ardea Biosciences, Inc. – Combination Treatment Modalities in Pipeline, 2012
Ardea Biosciences, Inc. – Phase III, 2012
Ardea Biosciences, Inc. – Phase II, 2012
Ardea Biosciences, Inc. – Phase I, 2012
Ardea Biosciences, Inc. – Pre-Clinical, 2012
Ardea Biosciences, Inc. – Pipeline By Therapeutic Class, 2012
Ardea Biosciences, Inc. - Pipeline By Target, 2012
Ardea Biosciences, Inc. – Pipeline By Route of Administration, 2012
Ardea Biosciences, Inc. – Pipeline Products By Mechanism of Action, 2012
Ardea Biosciences, Inc. – Recent Pipeline Updates, 2012
Ardea Biosciences, Inc. - Dormant Developmental Projects,2012
Ardea Biosciences, Inc. - Discontinued Pipeline Products, 2012
Ardea Biosciences, Inc., Subsidiaries
Ardea Biosciences, Inc., Deals Summary
Ardea Biosciences Acquires Intellectual Property And Other Assets From Valeant Pharma
Ardea Biosciences Enters Into License Agreement With Bayer HealthCare
Ardea Biosciences Completes Public Offering Of Common Stock For $166 Million
Ardea Biosciences Completes Exercise Of Underwriters’ Over-allotment Option For $82 Million
Ardea Biosciences Completes Public Offering Of $80.5 Million
Ardea Biosciences Completes Private Placement Of $31 Million
Ardea Biosciences Completes Private Placement $40 Million
Intrabiotics Pharma Completes Public Offering Of $44.85 Million
AstraZeneca To Acquire Ardea Biosciences, Gout Drug Maker, For $1.26 Billion
LIST OF FIGURES
Ardea Biosciences, Inc. – Pipeline by Indication, 2012
Ardea Biosciences, Inc. – Pipeline by Stage of Development, 2012
Ardea Biosciences, Inc. – Monotherapy Products in Pipeline, 2012
Ardea Biosciences, Inc. – Combination Treatment Modalities in Pipeline, 2012
Ardea Biosciences, Inc. – Pipeline By Therapeutic Class, 2012
Ardea Biosciences, Inc. - Pipeline By Target, 2012
Ardea Biosciences, Inc. - Pipeline Products By Mechanism of Action, 2012